PREBOOK THIS REPORT - SAVE 10%

Atopic Dermatitis Treatment Market Forecast - Epidemiology & Pipeline Analysis 2022-2027

TO BE PUBLISHED : Oct 2022 | Pages : 230

Up to $1050 off Prebook this report

THE GLOBAL ATOPIC DERMATITIS TREATMENT MARKET SIZE WAS VALUED AT USD 4.85 BILLION IN 2021 AND IS EXPECTED TO REACH USD 11.34 BILLION BY 2027, GROWING AT A CAGR OF 15.20%.

The Global Atopic Dermatitis Treatment Market Share, Size, & Trends Analysis Report by

  • Drug Class: Topical Steroids, Topical Calcineurin Inhibitors, Other class of Drugs
  • Gender Type: Men and Women
  • Age Group: 18 years and Below & 19 years and Above
  • Severity Type: Moderate, Mild, and Severe
  • Geography: North America (United States), APAC (China, Japan), and Europe (France, Germany, Italy, Spain & U.K.)

Prebook Tag
Licence Types What are these?
10 % OFF

Save 10% on this report.
Discount already applied

GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

icon-pages

230 Pages

icon-table

21 Tables

icon-chart

19 Charts

icon-region

3 Regions

icon-country

8 Countries

icon-company

33 Companies

icon-market

5 Market Segment

ATOPIC DERMATITIS TREATMENT MARKET REPORT SCOPE

Report Attribute Details
Market Size (2027) USD 11.34 Billion
Market Size (2021) USD 4.85 Billion
CAGR (2022-2027) 15.20%
Base Year 2021
Forecast Year 2022-2027
Market Segments Drug Class, Gender Type, Age Group, Severity Type, and Geography
Geographic Analysis North America, Europe, APAC
KEY PLAYERS LEO Pharma, Pfizer, Sanofi/Regeneron, Novartis, Incyte Corp, AbbVie, Eli Lilly and Company, Japan Tobacco Inc, Maruho Co., Ltd, Otsuka Holdings Co Ltd, Astellas Pharma Inc, and Stiefel Laboratories

MARKET INSIGHTS

The global atopic dermatitis treatment market was valued at USD 4.85 billion in 2021 and is expected to reach USD 11.34 billion by 2027, growing at a CAGR of 15.20% from 2022-2027. Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin condition that typically affects the face (cheeks), neck, arms, and legs but usually spares the groin and axillary regions. Atopic dermatitis (AD), also known as atopic eczema, is a chronic relapsing inflammatory skin condition. Atopic dermatitis (AD) is common worldwide. People of all ages, from newborns to adults 65 years and older, live with this condition. AD is associated with an increased risk of multiple comorbidities, including food allergy, asthma, allergic rhinitis, and mental health disorders. Due to such factors, the atopic dermatitis treatment market is growing immensely during the forecast period.

Atopic dermatitis is the most common type of eczema, affecting approximately 26 million people in the United States. AD is children's most common skin disease, with prevalence steadily increasing from 8% to 12% in the last two decades. It is characterized by a defect in the skin barrier, which allows allergens and other irritants to enter the skin, leading to an immune reaction and inflammation. This reaction produces a red, itchy rash, most frequently occurring on the face, arms and legs, and the rash can cover significant areas of the body. The rash causes significant pruritus (itching), which can lead to damage caused by scratching or rubbing and perpetuating an ‘itch-scratch’ cycle. Pediatric patients with atopic dermatitis can suffer from sleep disturbances, behavioral problems, irritability, crying, and interference with normal childhood activities and social functioning. Adults with AD also frequently suffer from sleep disturbances, emotional impacts, and impaired social functioning. Arizton estimates that the prevalent cases of AD were high in China, followed by U.S. and Japan in 2020. The increasing prevalence of atopic dermatitis is driving the growth of the atopic dermatitis treatment market.

Atopic Dermatitis Diagnosis

The exact cause of atopic dermatitis is unknown. Currently, no reliable biomarker which can distinguish the disease from other entities. However, the most commonly used biomarker is elevated total and/or allergen-specific serum IgE. The diagnosis of AD is based on the history and physical examination findings. Exposure to possible exacerbating factors, such as aeroallergens, irritating chemicals, foods, and emotional stress, should be investigated. Unfortunately, no specific laboratory findings or histologic features define atopic dermatitis.

Atopic Dermatitis Treatment

Most atopic dermatitis patients are treated with topical therapies, particularly low to mid-potency topical steroids and TCIs. These two classes of drugs constituted nearly all AD prescriptions. Despite their widespread use, existing topical therapies all possess substantial shortcomings:

  • Topical corticosteroids, in combination with Vitamin D creams and antihistamines, are the first line of treatment for AD. The topical steroids aim to provide short-term itch relief to break the itch-scratch reflex cycle – the primary cause of reinfection. Although in more mild cases, these therapies may be effective, in moderate/severe cases, long-term use (of steroids) tends to do more harm than benefit. Prolonged use damages and dries out the epidermal layer of skin, which, somewhat paradoxically, ends up actually worsening the itch-scratch complex.
  • Topical steroids pose a particular concern in pediatric patients due to the risk of systemic absorption, the consequent risk of HPA axis suppression, and potential developmental problems. Chronic use of topical steroids in AD patients is generally avoided.
  • Second-line agents include immunosuppressant medications such as topical calcineurin inhibitors, including Pimecrolimus (Elidel) and Tacrolimus (Protopic). Topical calcineurin inhibitors are generally seen as providing less symptomatic improvement than topical steroids and are also associated with some application site burning. In 2005 the FDA placed a boxed warning on the labels of both TCIs regarding a potential increased risk of cancers, especially lymphomas.
  • Other treatments include biologics, typically starting with interleukin inhibitors such as tralokinumab-idrm, dupilumab, and nemolizumab.
  • Topical treatments include PDE-4 inhibitors such as Crisaborole (Eucrisa) and Difamilast (Moizerto); JAK inhibitors such as Ruxolitinib (Opzelura) and Delgocitinib (Corectim Ointment).
  • Oral JAK inhibitors such as Abrocitinib (Cibinqo), Upadacitinib (Rinvoq), and Baricitinib (Olumiant) are used for the treatment of atopic dermatitis.

 

Atopic Dermatitis: Clinical Trials Scenario

The clinical trial portfolio contains 153+ trials in various development phases. Most industry-sponsored drugs in active clinical development for AD are in the Phase II stage. The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for atopic dermatitis have been in the mid-phase of development, with 47% of trials in Phase I/II & II and only 29% in Phase Phase II/III-III.

MARKET DRIVERS & TRENDS

Increasing Adoption for Biological Therapies
Biological therapies such as anti-interleukin antibodies are widely used for treatment in the atopic dermatitis treatment market. With Dupixent being the biologic approved for atopic dermatitis in 2017, there is a demand for therapies with novel MOAs that are less immunogenic than current offerings. Many new classes of therapies are looking to enter the market over the next few years. The biologics such as interleukin inhibitors are making inroads into the atopic dermatitis market owing to better clinical profile and convenient patient dosing.

Anticipated Launch of Emerging Drugs
A recent wave of biological products prescribed for treating AD will likely create a lucrative opportunity for growth in the atopic dermatitis treatment market. Despite the plethora of therapies currently available to patients with atopic dermatitis (AD), there is still room for improvement within the treatment space. Arizton anticipates the launch of five new agents among the 8MM, including two interleukin (IL) inhibitors (Lebrikizumab; CM-310), one topical Janus kinase (JAK) inhibitor (Delgocitinib), and two topical phosphodiesterase 4 (PDE-4) inhibitors (Roflumilast and JW-100). Launching these late-stage drugs will create an opportunity for growth in the global atopic dermatitis treatment market.

Focus on Novel Drugs with Novel Mechanism
The therapeutic agents targeting the IL-13/IL-31 axis have been proven to be very effective in AD, some are already in the therapeutic armamentarium, and others are in development. Over the next five years, Arizton expects to see a surge of innovation emerging from the research and development pipeline and a range of technology-enabled transformations that will expand the evidence-basis for interventions and bring measurable improvements to outcomes.

SEGMENTATION ANALYSIS

  • Drug Class: Topical Steroids are expected to account for a significant share of the global atopic dermatitis treatment market under the drug class segment. However, the other drug class is expected to be the fastest growing segment during the forecast period. Recently approved JAK and interleukin inhibitors are expected to drive the global atopic dermatitis therapeutics market during the forecast period.
  • Gender Type: Women are expected to dominate the global atopic dermatitis treatment market by gender type. This is because women have been at greater risk of atopic dermatitis in recent years.
  • Age Group: People aged 19 years and above are expected to account for most of the global atopic dermatitis market share by the age group segment.
  • Severity Type: Among the severity type, People with mild form are expected to account for a significant share of the global market. However, people with moderate form are expected to be the fastest-growing segment during the forecast period.

GEOGRAPHICAL ANALYSIS

In North America, the United States dominates the global atopic dermatitis treatment market due to the rise in healthcare affordability in the country, a rise in the knowledge and awareness amongst the people, and a rise in technological advancement in this region. However, Japan is expected to grow faster with a high CAGR in the atopic dermatitis drug market due to the rise in access and quality of healthcare, increased awareness about disease management, and rising healthcare expenditure in this region.

COMPETITIVE LANDSCAPE

The global atopic dermatitis treatment market is dominated by many companies offering generic drugs and selective pharma/biotech companies offering patented/commercial drugs for treating atopic dermatitis. The U.S. Food and Drug Administration (FDA) approved the interleukin antibody Dupixent (Dupilumab) for treating AD in 2017. This marked the arrival of interleukin biologics in this treatment landscape. Recently the FDA approved interleukins such as Tralokinumab-idrm (adbry) in 2021, and PMDA approved Mitchga (Nemolizumab) in 2022 for treating atopic dermatitis. Although generic products continue to capture significant atopic dermatitis treatment market share, the arrival of biologics and other targeted therapies indicate a paradigm shift in this therapeutic space through the forecast period.

The emerging therapeutics developed for atopic dermatitis include Lebrikizumab, CM-310, Tapinarof, Roflumilast, Rocatinlimab, and many others. Launching these novel emerging drugs will shift the atopic dermatitis therapeutics paradigm soon. With more than 153 molecules in various stages of development, it is expected that new vendors are likely to enter the market with a novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating atopic dermatitis.

Companies such as AbbVie, Pfizer, Novartis, LEO Pharma, Sanofi/Regeneron, Incyte Corp, Maruho Co., Ltd, Eli Lilly and Company, Japan Tobacco Inc, and others, etc., are the major players in the global atopic dermatitis treatment market. These players are focused on adopting growth strategies to strengthen their product portfolio.

These companies have adopted strategies such as collaborations & acquisitions, expansion of geographical footprint, investments in research & development, and manufacture of novel drugs to compete in the global atopic dermatitis treatment market. Other prominent players operating in the global atopic dermatitis treatment market include Arcutis Biotherapeutics, Kyowa Hakko Kirin, Dermavant Sciences, Vanda Pharmaceuticals, CARA Therapeutics, and many others.

REPORT COVERS

  • Detailed overview of atopic dermatitis treatment market, including disease definition, classification, diagnosis, and treatment pattern
  • Overview of the global trends of AD in the eight major markets (8MM)
  • Historical, current, and projected patient pool of atopic dermatitis in the eight major markets (8MM) for 2018 – 2027
  • In-depth market segment analysis, including products, treatment, and competitor analysis
  • Atopic dermatitis treatment market share of the market players, company profiles, product specifications, and competitive landscape
  • Comprehensive data on emerging trends, market drivers, growth opportunities, and restraints
  • Detailed overview of marketed drugs with key coverage of developmental activities, including sponsor name, approved indication, territory, collaborations, licensing, mergers and acquisitions, regulatory designations, and other product-related activities
  • Detailed overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Atopic Dermatitis across the complete product development cycle, including all clinical and non-clinical stages
  • Detailed overview of clinical trial activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and geography type for atopic dermatitis across all clinical stages
  • Coverage of dormant and discontinued pipeline projects along with the reasons across the atopic dermatitis treatment market
  • Coverage of significant milestones (product approvals/launches timelines, clinical trial result publications, regulatory designations, licensing & collaborations, research & development progress of pipeline assets) in the atopic dermatitis space

Frequently Asked Questions

How big is the global atopic dermatitis treatment market?

The global atopic dermatitis treatment market size is expected to reach USD 11.34 billion by 2027.

What is the growth rate of the global atopic dermatitis treatment market?

The global atopic dermatitis treatment market is growing with a CAGR of 15.20% from 2022-2027.

What factors drive the growth of the atopic dermatitis treatment market?

The increasing demand for biologics, a rising burden of allergic reactions, and the anticipated launch of emerging drugs are prime factors driving the market.

Who are the leading vendors operating in the global atopic dermatitis treatment market?

LEO Pharma, Pfizer, Sanofi/Regeneron, Novartis, Incyte Corp, AbbVie, Eli Lilly and Company, Japan Tobacco Inc, Maruho Co., Ltd, Otsuka Holdings Co Ltd, Astellas Pharma Inc, and Stiefel Laboratories are the key players in the global atopic dermatitis treatment market.

Which region holds the largest global atopic dermatitis treatment market share?

In North America, the United States dominates the global atopic dermatitis treatment market due to the rise in healthcare affordability in the country, a rise in knowledge and awareness amongst the people, and a rise in technological advancement in this region.

Download Free Sample

The global atopic dermatitis treatment market is expected to grow at a CAGR of approximately 15.20% from 2022 to 2027.

The following factors are likely to contribute to the growth of the global atopic dermatitis treatment market during the forecast period:

  • Increasing Demand for Biologics
  • Increasing Burden of Allergic Reactions
  • Anticipated Launch of Emerging Drugs

Base Year: 2021

Forecast Year: 2022-2027

The report considers the present scenario of the atopic dermatitis treatment market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.

Key Vendors

  • LEO Pharma
    • Company Overview
    • Product Offerings
  • Pfizer
  • Sanofi/Regeneron
  • Novartis
  • Incyte Corp
  • AbbVie
  • Eli Lilly and Company
  • Japan Tobacco Inc
  • Maruho Co., Ltd
  • Otsuka Holdings Co Ltd
  • Astellas Pharma Inc
  • Stiefel Laboratories

Other Prominent Vendors

  • Arcutis Biotherapeutics
    • Company Overview
    • Product Offerings
  • Kyowa Hakko Kirin
  • Vanda Pharmaceuticals
  • Dermavant Sciences
  • CARA Therapeutics
  • AstraZeneca Plc (AstraZeneca)
  • UNION therapeutics
  • Asana
  • Evelo Biosciences
  • BiomX
  • AOBiome Therapeutics, Inc.
  • Amytrx
  • RAPT Therapeutics
  • Oneness Biotech
  • VYNE’s Therapeutics
  • BenevolentAI Ltd
  • vTv Therapeutics Inc.
  • Botanix Pharmaceuticals Ltd (BOT)
  • selectION, Inc.
  • Inmagene
  • Novan, Inc.

Segmentation by Drug Class

  • Topical Steroids
  • Topical Calcineurin Inhibitors
  • Other Class of Drugs

Segmentation by Gender Type

  • Men
  • Women

Segmentation by Age Group

  • 18 years and Below
  • 19 years and Above

Segmentation by Severity Type

  • Moderate
  • Mild
  • Severe

Segmentation by Geography

  • North America
    • U.S.
  • APAC
    • China
    • Japan
  • Europe
    • France
    • Germany
    • UK
    • Italy
    • Spain

For more details, please reach us at enquiry@arizton.com

For more details, please reach us at enquiry@arizton.com

Select a license type that suits your business needs

single-user Single User Licence
$3000.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5-user 5 User Licence
$3400.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
corporate.png Corporate Licence
$4200.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
datasheet.png Datasheet Licence
$1200.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Our Clients

Prebook Tag
Licence Types What are these?
10 % OFF

Save 10% on this report.
Discount already applied

Interested in data center portfolio for this report?
Click here

Our Clients Speak

erick

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Want to Customize the Report?

Click Here

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date